Status | Study |
Terminated |
Study Name: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Condition: Peripheral T-Cell Lymphoma Date: 2013-04-24 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day |
Completed |
Study Name: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2013-02-25 Interventions: Drug: Alemtuzumab Consolidation after CHOP induction |
Completed |
Study Name: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2012-08-30 Interventions: Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT |
Completed |
Study Name: Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2012-08-10 Interventions: Drug: GDPT regimen GDPT regime |
Completed |
Study Name: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-Cell Lymphoma Date: 2012-05-30 Interventions: Biological: KW-0761 (mogamulizumab) 1 mg/kg administered intravenously weekly x 4 then every other week |
Active, not recruiting |
Study Name: A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Condition: Lymphoma, T-cell, Peripheral Date: 2011-10-18 Interventions: Drug: Romidepsin Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle |
Completed |
Study Name: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2011-07-18 Interventions: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da |
Recruiting |
Study Name: T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma Condition: Lymphoma, T-Cell, Peripheral Date: 2010-06-10 |
Active, not recruiting |
Study Name: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Condition: Peripheral T-cell Lymphoma Date: 2010-04-23 |
Completed |
Study Name: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2009-03-19 Interventions: Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e |